Related references
Note: Only part of the references are listed.Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Raghuveer Singh Mali et al.
HAEMATOLOGICA (2021)
The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors
Rodion A. Velichinskii et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
Ayano Nakamura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia
Zhenhui Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model
Mushtaq A. Ansari et al.
MOLECULES (2021)
Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation
Alena Machuldova et al.
FRONTIERS IN IMMUNOLOGY (2021)
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia
Noortje van Gils et al.
FRONTIERS IN ONCOLOGY (2021)
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia
Roberto Limongello et al.
FRONTIERS IN IMMUNOLOGY (2021)
Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity
Eric Alves et al.
FRONTIERS IN IMMUNOLOGY (2021)
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
Heikki Kuusanmaki et al.
HAEMATOLOGICA (2020)
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome
B. Bouchacourt et al.
ANNALS OF HEMATOLOGY (2020)
Artemisinin sensitizes tumor cells to NK cell-mediated cytolysis
Zhen Lu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
Jan Philipp Bewersdorf et al.
HAEMATOLOGICA (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
CXCR3 antagonist AMG487 inhibits glucocorticoid-induced tumor necrosis factor-receptor-related protein and inflammatory mediators in CD45 expressing cells in collagen-induced arthritis mouse model
Saleh A. Bakheet et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro
Satsuki Murakami et al.
HEMATOLOGICAL ONCOLOGY (2020)
CXC chemokine receptor 3 antagonist AMG487 shows potent anti-arthritic effects on collagen-induced arthritis by modifying B cell inflammatory profile
Saleh A. Bakheet et al.
IMMUNOLOGY LETTERS (2020)
Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics
Inke De haes et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Natural killer cell-based immunotherapy for acute myeloid leukemia
Jing Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
Bachar Samra et al.
FRONTIERS IN ONCOLOGY (2020)
Natural killer group 2D receptor and its ligands in cancer immune escape
Shixin Duan et al.
MOLECULAR CANCER (2019)
Venetoclax-based therapies for acute myeloid leukemia
Veronica A. Guerra et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
Norimichi Hattori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Shifting paradigms in the treatment of older adults with AML
Thomas W. LeBlanc et al.
SEMINARS IN HEMATOLOGY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2019)
Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention
Rosa Molfetta et al.
FRONTIERS IN IMMUNOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
CXCR3 antagonist AMG487 suppresses rheumatoid arthritis pathogenesis and progression by shifting the Th17/Treg cell balance
Saleh A. Bakheet et al.
CELLULAR SIGNALLING (2019)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2019)
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
Iris de Weerdt et al.
BLOOD ADVANCES (2019)
Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
Mohamed Rahmani et al.
CANCER RESEARCH (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival
Charlotte Viant et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Sunitinib Induces NK-κB- dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells
Yu-xian Huang et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
L. Chen et al.
LEUKEMIA (2017)
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
Brian C. Shaffer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Antonio Curti et al.
CLINICAL CANCER RESEARCH (2016)
NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells
Daniela Schilling et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
A. Baragano Raneros et al.
GENES AND IMMUNITY (2015)
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
Sisi He et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity
Shuli Zhao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2
Yuxian Huang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Share Paper
